TCRT (Alaunos Therapeutics) Total Stockholders Equity: $1.29 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TCRT Alaunos Therapeutics Inc TCRT
29 GF Score
Price $1.88
GF Value $0.68
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Alaunos Therapeutics Total Stockholders Equity?

Alaunos Therapeutics TCRT 29 Total Stockholders Equity is $1.29 Mil as of Mar. 2026. GuruFocus rates TCRT with a GF Score™ of 29/100 and a GF Value™ of $0.68 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Alaunos Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $1.29 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Alaunos Therapeutics's Book Value per Share for the quarter that ended in Mar. 2026 was $0.54. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Alaunos Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2026 was 0.00.

Alaunos Therapeutics  (NAS:TCRT) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Alaunos Therapeutics's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(1.288-0)/2.378
=0.54

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Alaunos Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 1.288
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alaunos Therapeutics Total Stockholders Equity Related Terms

Alaunos Therapeutics Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Alaunos Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alaunos Therapeutics Total Stockholders Equity Chart

Alaunos Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 58.06 38.56 6.31 2.06 2.15

Alaunos Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.06 3.66 2.80 2.15 1.29
TCRT
29GF Score
Alaunos Therapeutics Inc TCRT
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $1.29 Mil mean?
Alaunos Therapeutics (TCRT) has a Total Stockholders Equity of $1.29 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Alaunos Therapeutics and its competitors.
Is Alaunos Therapeutics' Total Stockholders Equity too high?
Alaunos Therapeutics' current Total Stockholders Equity is $1.29 Mil. Overall, Alaunos Therapeutics has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alaunos Therapeutics' Total Stockholders Equity compare to JAGX and LABT?
Alaunos Therapeutics' Total Stockholders Equity of $1.29 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Alaunos Therapeutics and its competitors. Alaunos Therapeutics's current Total Stockholders Equity is $1.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alaunos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Alaunos Therapeutics (TCRT) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.68, compared to a current price of $1.88 — trading 176.5% above its estimated fair value. The current Total Stockholders Equity is $1.29 Mil. Alaunos Therapeutics' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Alaunos Therapeutics (TCRT), the current Total Stockholders Equity is $1.29 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alaunos Therapeutics (TCRT) Overvalued in 2026?

Based on GuruFocus' analysis, Alaunos Therapeutics stock appears to be overvalued. The current stock price of $1.88 is trading 176.5% above its estimated GF Value™ of $0.68. GuruFocus considers Alaunos Therapeutics to be Significantly Overvalued.

Key valuation signals for TCRT:

  • Total Stockholders Equity: $1.29 Mil
  • GF Value™: $0.68 vs. price of $1.88 (176.5% above fair value)
  • GF Score™: 29/100 with 4 warning signs

No single metric tells the full story. See the TCRT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alaunos Therapeutics Business Description

Address 501 East Las Olas Boulevard, Suite 300, Fort Lauderdale, FL, USA, 33301
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
29GF Score

Get the complete analysis for TCRT

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.88
Price
$0.68
GF Value